TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16322108

Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (defined as at least 6.3% residual volume at four hours)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: SF 36 physical composite score (PCS)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: SF 36 mental composite score (MCS)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Higher symptom scores for fullness, epigastric pain, and nausea
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Higher baseline nausea symptom score, lower gastric emptying rates at one hour, and lower body mass index
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Female sex, epigastric pain, and nausea
Number of subjects: 864
Study: 10227503

Group type: EXPERIMENTAL
Intervention: Sublingual 1-hyoscyamine sulfate
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 110
Study: 9772597

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine combined with cord blood infusion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cord blood infusion solely
Number of subjects: 48
Study: 1832701

Group type: EXPERIMENTAL
Intervention: 3 capsules of fish oil daily for 6 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 6 capsules of fish oil daily for 6 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 9 capsules of fish oil daily for 6 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 12 capsules of fish oil daily for 6 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All doses except the lowest
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Highest dose (12 capsules)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Two middle doses (6 and 9 capsules)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids consumption
Number of subjects: 28
Study: 6227208

Group type: EXPERIMENTAL
Intervention: Blood pressure during isometric exercise (in upper blood pressure range)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 24 hour urinary noradrenaline excretion (in upper blood pressure range)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Plasma aldosterone (in upper blood pressure range)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Blood glucose (in intermediate blood pressure range)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Plasma insulin (in intermediate blood pressure range)
Number of subjects: 120
Study: 31527690

Group type: EXPERIMENTAL
Intervention: Genetic lipid scores for triglycerides (TG)
Number of subjects: 4080

Group type: EXPERIMENTAL
Intervention: Genetic lipid scores for high density lipoprotein cholesterol (HDL)
Number of subjects: 4080

Group type: EXPERIMENTAL
Intervention: Genetic lipid scores for low density lipoprotein cholesterol (LDL)
Number of subjects: 4080

Group type: EXPERIMENTAL
Intervention: Genetic lipid scores for total cholesterol (TC)
Number of subjects: 4080

Group type: EXPERIMENTAL
Intervention: Statin use (overall)
Number of subjects: 4080

Group type: EXPERIMENTAL
Intervention: Lipophilic statins
Number of subjects: 4080
Study: 29962429

Group type: EXPERIMENTAL
Intervention: PYC chewing gum (2.5 mg per piece, 2 pieces, 6 times daily for 15 min)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo gum (sugar-free gums)
Number of subjects: 21
Study: 26960972

Group type: EXPERIMENTAL
Intervention: Enhanced narrative game group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-monitoring group
Number of subjects: 0
Study: 25179924

Group type: EXPERIMENTAL
Intervention: Diagnosis-first condition (non-analytic reasoning)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Features-first condition (analytic reasoning)
Number of subjects: 73
Study: 21853290

Group type: EXPERIMENTAL
Intervention: 60 mg tolvaptan with 240 mL of reconstituted grapefruit juice
Number of subjects: 20

Group type: COMPARATOR
Intervention: 60 mg tolvaptan with 240 mL of water
Number of subjects: 20
Study: 20805116

Group type: EXPERIMENTAL
Intervention: Bilateral internal mammary arteries (BIMA)
Number of subjects: 3102

Group type: COMPARATOR
Intervention: Single internal mammary artery (SIMA)
Number of subjects: 3102
Study: 18052518

Group type: EXPERIMENTAL
Intervention: Kids Living Fit (KLF) program
Number of subjects: 185

Group type: COMPARATOR
Intervention: No-intervention/contrast group
Number of subjects: 185
Study: 15617666

Group type: EXPERIMENTAL
Intervention: Difficult feature search
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficult conjunction search
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial-configuration search
Number of subjects: 0
Study: 11877767

Group type: EXPERIMENTAL
Intervention: High-dose myeloablative radioimmunotherapy with (131)I-labeled chimeric anti-CD20 antibody C2B8 at doses of 261-495 mCi, with a protein dose of 2.5 mg/kg (or 10 mg/kg for one patient with splenomegaly).
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-dose myeloablative radioimmunotherapy with (131)I-labeled chimeric anti-CD20 antibody C2B8.
Number of subjects: 7
Study: 10223779

Group type: EXPERIMENTAL
Intervention: 50 microg/h lanreotide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 microg/h lanreotide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 microg/h lanreotide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All doses of lanreotide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7797662

Group type: COMPARATOR
Intervention: Ultrasonography in controls
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ultrasonography in Tietze's syndrome
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ultrasonography correlation with CT
Number of subjects: 22
Study: 2367653

Group type: EXPERIMENTAL
Intervention: Blood patch technique (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No blood patch (group B)
Number of subjects: 100
Study: 30797042

Group type: EXPERIMENTAL
Intervention: Buprenorphine Bridge Treatment (BBT)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 320
Study: 29848186

Group type: EXPERIMENTAL
Intervention: Patient and physician interventions (Cohort C)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Physician intervention (Cohort B)
Number of subjects: 600

Group type: COMPARATOR
Intervention: No interventions (Cohort A)
Number of subjects: 600
Study: 26801394

Group type: EXPERIMENTAL
Intervention: Cancer Home-Life Intervention in addition to usual care
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 272
Study: 25106091

Group type: EXPERIMENTAL
Intervention: Food Dudes intervention (rewards, peer-modeling, food exposure)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group (only provided with fruits and vegetables)
Number of subjects: 560
Study: 21926656

Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study: 20589922

Group type: EXPERIMENTAL
Intervention: 3 mg paliperidone ER OROS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 9 mg paliperidone ER OROS
Number of subjects: 24
Study: 17379842

Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Colestimide (3000 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normocholesterolemic controls (11 age-matched volunteers)
Number of subjects: 12
Study: 16236837

Group type: EXPERIMENTAL
Intervention: Roaring Adventures of Puff asthma education program
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study: 12193911

Group type: COMPARATOR
Intervention: Intravenous oxytocin (1 to 4 mU/min) and placebo intravaginal misoprostol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 microg, repeated at 4 hourly intervals if <3 uterine contractions per 10 minutes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 0
Study: 10192667

Group type: EXPERIMENTAL
Intervention: ED-based Asthma Observation Unit (AOU)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Inpatient hospitalization (control group)
Number of subjects: 163
Study: 8520442

Group type: EXPERIMENTAL
Intervention: Albendazole (15 mg/kg/day for 7 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2361796

Group type: EXPERIMENTAL
Intervention: Topical aluminium chloride hexahydrate 20% W/W ethanol (ACH) applied daily for 4 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated palms (control)
Number of subjects: 12
Study: 415471

Group type: EXPERIMENTAL
Intervention: Lisuride 300 microgram orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisuride 100 microgram orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisuride 200 microgram orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulpiride 50 mg injection
Number of subjects: 0
Study: 30444276

Group type: EXPERIMENTAL
Intervention: 10 kHz Peripheral Nerve Stimulation (PNS) for 4 hours
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 10 kHz Peripheral Nerve Stimulation (PNS) for 2 hours
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (PNS turned OFF)
Number of subjects: 69

Group type: COMPARATOR
Intervention: 10 kHz Spinal Cord Stimulation (SCS)
Number of subjects: 69
Study: 27696656

Group type: EXPERIMENTAL
Intervention: Single reinduction course
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: Double reinduction courses
Number of subjects: 1366

Group type: COMPARATOR
Intervention: Triple intrathecal therapy without cranial radiation (CrRT)
Number of subjects: 1366

Group type: EXPERIMENTAL
Intervention: MLL or BCR-ABL1 positive patients
Number of subjects: 1366
Study: 25680375

Group type: EXPERIMENTAL
Intervention: Targeted therapy (specific agents not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 23640544

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) delivered by a psychologist plus treatment as usual (education, reassurance, and symptom management strategies)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treatment as usual (education, reassurance, and symptom management strategies)
Number of subjects: 28
Study: 21533329

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 19387331

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham-stimulated control
Number of subjects: 26
Study: 17967668

Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine (0.5 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15090770

Group type: EXPERIMENTAL
Intervention: GW433908/ritonavir (908/r) 1400 mg/200 mg, once daily (q.d.)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Nelfinavir 1250 mg, twice daily (b.i.d.)
Number of subjects: 649
Study: 11274623

Group type: EXPERIMENTAL
Intervention: Eradication therapy (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, all given four times daily for one week)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Omeprazole (20 mg daily for six months)
Number of subjects: 400
Study: 9636912

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo circuits (n = 10)
Number of subjects: 21
Study: 7872715

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control Ovaries
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Malignant Tumour Tissue
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EGF or IGF-1
Number of subjects: 27
Study: 2835427

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28503741

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study: 28827250

Group type: COMPARATOR
Intervention: Short document
Number of subjects: 460

Group type: COMPARATOR
Intervention: Structured response
Number of subjects: 460
Study: 26301701

Group type: EXPERIMENTAL
Intervention: brexpiprazole 2 mg/d
Number of subjects: 353

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 353
Study: 23178320

Group type: EXPERIMENTAL
Intervention: Low nicotine (LN, 0.4 mg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High nicotine (HN, 11.4-12.8 mg/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate nicotine (IN, 5.7-5.8 mg/g)
Number of subjects: 0
Study: 21951091

Group type: EXPERIMENTAL
Intervention: Covered Wallstent (CWS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: DoubleLayer stent (DLS)
Number of subjects: 113
Study: 18297436

Group type: EXPERIMENTAL
Intervention: Intensive treatment schedule (three treatment sessions per week for the first 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Original treatment schedule (weekly treatment)
Number of subjects: 30
Study: 16571158

Group type: EXPERIMENTAL
Intervention: Microalgae oil (0.94 g DHA/d)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 114
Study: 15289837

Group type: EXPERIMENTAL
Intervention: CDDP (80 mg/m(2)) as a continuous 2‐h intravenous infusion on day 1 and 5‐FU (700 mg/m(2)) as a continuous intravenous infusion on days 2‐5 (Group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: 5‐FU (700 mg/m(2)) as a continuous intravenous infusion on days 1‐4, followed by CDDP (80 mg/m(2)) as a continuous 2‐h intravenous infusion on day 5 (Group B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CDDP before 5‐FU
Number of subjects: 74

Group type: COMPARATOR
Intervention: 5‐FU before CDDP
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study: 11762807

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine at 60 mg/m2/week for the first three administrations, then increased to 80 mg/m2/week
Number of subjects: 115

Group type: COMPARATOR
Intervention: Intravenous (i.v.) vinorelbine at 30 mg/m2/week
Number of subjects: 115
Study: 8996153

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (CT) plus radiotherapy (RT): cisplatin 75 mg/m2 on day 1 and fluorouracil (5FU) 1,000 mg/m2/d on days 1 to 4 every 4 weeks with RT and every 3 weeks post‐RT.
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (CT) plus radiotherapy (RT): additional patients treated with the same combined therapy.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone: 64 Gy RT.
Number of subjects: 123
Study: 8435253

Group type: EXPERIMENTAL
Intervention: Oral diazepam 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3315513

Group type: EXPERIMENTAL
Intervention: Insulin bolus at 2300 h (2.1 +/- 0.2 U)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin bolus at 0100 h (after reactivating the pump at 1.05 +/- 0.11 U/h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Reference control group (pump functioning normally throughout the night)
Number of subjects: 9
Study: 29596158

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) combined with exercise therapy (ET)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Exercise therapy (ET) alone
Number of subjects: 185
Study: 27576085

Group type: EXPERIMENTAL
Intervention: CPR-instructor-course (4h preparatory seminar and teaching session in BLS for school children)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 24461109

Group type: COMPARATOR
Intervention: Pasireotide 600 μg sc bid alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Metformin 500 mg po bid
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Nateglinide 60 mg po tid
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Vildagliptin 50 mg po bid
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Liraglutide 0.6 mg sc qd
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Nateglinide
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Metformin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Liraglutide
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg sc bid + Vildagliptin
Number of subjects: 90
Study: 22648092

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (330 ml/day for four weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control drink (330 ml/day for four weeks)
Number of subjects: 51
Study: 20099369

Group type: EXPERIMENTAL
Intervention: 10 mg of ebastine plus 120 mg of pseudoephedrine complex
Number of subjects: 0
Study: 18184907

Group type: EXPERIMENTAL
Intervention: Individualized lifestyle intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 522
Study: 16448783

Group type: EXPERIMENTAL
Intervention: FTND-ST
Number of subjects: 42
Study: 12551863

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg BID)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10406065

Group type: EXPERIMENTAL
Intervention: Primary PTCA (percutaneous transluminal coronary angioplasty)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine IABP insertion during primary PTCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive pharmacotherapy with potent antiplatelet agents
Number of subjects: 0
Study: 7574856

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 20 mg once daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2625539

Group type: EXPERIMENTAL
Intervention: Evening testing (15:00 h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Morning testing (10:00 h)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CFF (Critical Flicker Fusion)
Number of subjects: 24
Study: 1058542

Group type: EXPERIMENTAL
Intervention: Four times repeated spray application
Number of subjects: 21

Group type: COMPARATOR
Intervention: Antiseptics added to the spray
Number of subjects: 21
Study: 31933439

Group type: EXPERIMENTAL
Intervention: Verbal attention condition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nonverbal attention condition
Number of subjects: 12
Study: 31002426

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 1
Study: 28364475

Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention
Number of subjects: 380

Group type: COMPARATOR
Intervention: Attention control arm
Number of subjects: 380
Study: 24997757

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol and gestodene patch (delivering low doses equivalent to 0.02 mg EE and 0.06 mg GSD) applied once weekly for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: CYP3A4 inhibitors (erythromycin and ketoconazole) administered concurrently with the patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (CYP3A4 substrate) administered alone and after 3 weeks of concurrent patch application
Number of subjects: 0
Study: 23351464

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention and optimal medical therapy
Number of subjects: 283

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 283
Study: 21983118

Group type: EXPERIMENTAL
Intervention: Carnidrop
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Optive
Number of subjects: 27

Group type: COMPARATOR
Intervention: Blu Sal
Number of subjects: 27
Study: 19136338

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 48
Study: 17715456

Group type: EXPERIMENTAL
Intervention: Saccadic eye movements
Number of subjects: 15

Group type: COMPARATOR
Intervention: Blinking patterns
Number of subjects: 15
Study: 15089890

Group type: EXPERIMENTAL
Intervention: Licofelone 200 mg b.i.d. (n = 30)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Licofelone 400 mg b.i.d. (n = 30)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d. (n = 30)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (n = 31)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Licofelone 200 mg b.i.d.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Licofelone 400 mg b.i.d.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Licofelone 200 mg b.i.d. or Naproxen therapy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Licofelone or Naproxen therapy
Number of subjects: 121
Study: 11455257

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg per day
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1 g twice daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both MMF and AZA
Number of subjects: 81
Study: 9726387

Group type: EXPERIMENTAL
Intervention: LAC (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., clarithromycin 250 mg b.d.)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: LAM (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: LCM (lansoprazole 30 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: OAM (omeprazole 20 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.)
Number of subjects: 262
Study: 8070443

Group type: EXPERIMENTAL
Intervention: Fluconazole (3 mg/kg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ketoconazole (7 mg/kg/day)
Number of subjects: 46